| HOME >> MEDICINE >> TECHNOLOGY |
Injectables or Oral Drugs - The Road Ahead II-2
Conventional Oral Drugs to Face the Heat Too II-2
New Drugs yet to Gain Mainstream Status II-2
Sizing the Market II-3
2. INDUSTRY OVERVIEW II-4
Issues with Traditional Drugs Fueling the Hunt for New
Anticoagulants II-4
New Therapies: Need of the Hour II-4
Drug Advancements Drive Anticoagulant Market II-4
Niche Markets - The New Target for Drug Makers II-4
Anticoagulant Therapy in IPF: Reduces Mortality Risk II-5
Anticoagulants to Lose UA/AMI Markets to Antiplatelets II-5
An Opportunity to Grow Further II-5
Warfarin & Heparins: The Former Market Leaders II-5
Generics Drugs Prevail in the Anticoagulant Market II-6
Concern Over Underutilization of Warfarin II-6
Novel Oral Anticoagulants to Turbo-Charge Market Growth II-7
Hurdles Exist for New Oral Agents II-7
The Merits and Demerits of New Age Anticoagulants II-7
Lack of Adequate Trials Mar Pediatric Anticoagulants Market II-8
Improved Anticoagulant Agents for Children Group II-8
Growing Demand for Self-Testing II-8
LMWHs Ease Outpatient Management II-8
Novel Heparins Enhance Market Potential II-9
A Focus on Failed or Withdrawn Agents in Recent Past II-9
Idraparinux and Idrabiotaparinux Sodium - Sanofi's
Discontinued Agents II-9
Lack of Statistical Significance Leads to Culmination of
Tecarfarin's Development II-10
Sofigatran - A Failed Agent from Mitsubishi Tanabe Pharma II-10
3. ORAL ANTICOAGULANT AGENTS II-11
Traditional Oral Anticoagulants II-11
Warfarin II-11
Advantages and Alternatives II-11
Side Effects II-11
Limitations II-12
Coumadin - The Branded Warfarin II-12
Novel Oral Anticoagulants II-12
Dabigatran Etexilate (Pradaxa) II-12
Table 1: Pradaxa and Warfari
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |